Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour

被引:31
作者
Baudry, D
Faussillon, M
Cabanis, MO
Rigolet, M
Zucker, JM
Patte, C
Sarnacki, S
Boccon-Gibod, L
Junien, C
Jeanpierre, C [1 ]
机构
[1] Univ Paris 05, Hop Necker Enfants Malad, INSERM, U383, F-75743 Paris 15, France
[2] Inst Curie, F-75248 Paris, France
[3] Inst Gustave Roussy, F-94805 Villejuif, France
[4] Hop Necker Enfants Malad, Clin Chirurg Infantile, F-75743 Paris 15, France
[5] Hop Armand Trousseau, Serv Anat Pathol, F-75012 Paris, France
关键词
Wilms' tumour; expression profiling; WTI splicing; prognosis;
D O I
10.1038/sj.onc.1205752
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Wilms' tumour (WT) or nephroblastoma is the most frequent kidney cancer in children. In a previous study, we reported alterations to WTI transcription in 90% of WT tested, with decreased exon 5 +/- isoform ratio being the most frequent alteration (56% of WT). We now report an approach based on cDNA profiling of tumour pools to identify genes likely to be dysregulated in association with a decreased WTI exon 5 +/- ratio. We compared the expression profiles of pools of tumours classified according to whether this isoform imbalance was present (five tumours) or not (four tumours), using Atlas Cancer cDNA expression arrays. Fourteen of 588 genes tested displayed specific up-regulation (CCND2, PCNA, N-MYC, E2F3, TOP2A, PAK1, DCC and PCDH2) or down-regulation (VEGF, IGFBP5, TIMP3, ARHB, C-FOS and CD9) in the pool of tumours with decreased exon 5 +/- ratio. These results were validated by RT-PCR analysis of four genes (CCND2, PCNA, VEGF and IGFBP5). We extended the analysis of VEGF expression to 51 tumours by real-time RTPCR and ascertained differential expression of this gene associated with WTI expression pattern. Moreover, our results suggest that the VEGF expression level may be of prognosis relevance for relapsed patients.
引用
收藏
页码:5566 / 5573
页数:8
相关论文
共 41 条
[1]  
Bachman KE, 1999, CANCER RES, V59, P798
[2]   Donor splice-site mutations in WT1 are responsible for Frasier syndrome [J].
Barbaux, S ;
Niaudet, P ;
Gubler, MC ;
Grunfeld, JP ;
Jaubert, F ;
Kuttenn, F ;
Fekete, CN ;
SouleyreauTherville, N ;
Thibaud, E ;
Fellous, M ;
McElreavey, K .
NATURE GENETICS, 1997, 17 (04) :467-470
[3]  
Baudry D, 2000, CLIN CANCER RES, V6, P3957
[4]   Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA [J].
Çeliker, MY ;
Wang, M ;
Atsidaftos, E ;
Liu, X ;
Liu, YE ;
Jiang, Y ;
Valderrama, E ;
Goldberg, ID ;
Shi, YE .
ONCOGENE, 2001, 20 (32) :4337-4343
[5]   WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes [J].
Davies, RC ;
Calvio, C ;
Bratt, E ;
Larsson, SH ;
Lamond, AI ;
Hastie, ND .
GENES & DEVELOPMENT, 1998, 12 (20) :3217-3225
[6]  
DECLERCK YA, 1992, CANCER RES, V52, P701
[7]  
Englert C, 1997, CANCER RES, V57, P1429
[8]  
Granzen B, 2001, ANTICANCER RES, V21, P771
[9]   Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition [J].
Guan, LS ;
Rauchman, M ;
Wang, ZY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (42) :27047-27050
[10]   Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation [J].
Hammes, A ;
Guo, JK ;
Lutsch, G ;
Leheste, JR ;
Landrock, D ;
Ziegler, U ;
Gubler, MC ;
Schedl, A .
CELL, 2001, 106 (03) :319-329